| IPR | insulin production rate; intraparenchymal resistance; ipratropium |
|---|
| IB | Ipratropium Bromide |
|---|
| ipratropium | <chemical> A muscarinic antagonist structurally related to atropine but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic. Pharmacological action: anti-arrhythmia agents, bronchodilator agents, muscarinic antagonists, parasympatholytics. Chemical name: 8-Azoniabicyclo(3.2.1)octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, (endo,syn)-(+-)- (12 Dec 1998) |
|---|
Synonyms : (endo, syn)-(+-)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane, Atrovent, Ipratropium Bromide, Ipratropium Bromide, (endo, anti)-Isomer, Ipratropium Bromide, (exo, syn)-Isomer, Ipratropium Bromide, endo-Isomer
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|---|---|---|---|
|
컴비벤트에어로솔 - 새창
|
Boehringer Ingelheim |
E04260101 | Ipratropium Bromide, Salbutamol sulfate | 전문의약품 | 급여 |
|
아트로벤트흡입액유디비 - 새창
|
Boehringer Ingelheim |
E04260021 | Ipratropium Bromide | 일반의약품 | 급여 |
|
리노벤트비액 - 새창
|
한림제약 |
A37802971 | Ipratropium Bromide | 전문의약품 | 급여 |
|
아트로벤트에어로솔 - 새창
|
한국베링거인겔하임 |
A07600521 | Ipratropium Bromide | 일반의약품 | 급여 |
|
아트로벤트네잘분무액 - 새창
|
Boehringer Ingelheim |
E04260131 | Ipratropium Bromide | 전문의약품 | 삭제 |
|
아트로벤트흡입액유디비250mcg/2ml - 새창
|
Boehringer Ingelheim |
E04260141 | Ipratropium Bromide | 일반의약품 | 급여 |
|
컴비벤트유디비흡입액 - 새창
|
Boehringer Ingelheim |
E04260121 | Ipratropium Bromide, Salbutamol sulfate | 전문의약품 | 삭제 |
|
피엠에스이프라트로피움나잘스프레이0.03% - 새창
|
제이텍바이오젠 |
W11960271 | Ipratropium Bromide | 전문의약품 | 급여 |
|
아벤트로흡입액 - 새창
|
건일제약 |
A03853981 | Ipratropium Bromide | 일반의약품 | 급여 |
|
이프라돔흡입액 - 새창
|
대한약품공업 |
A02751771 | Ipratropium Bromide | 일반의약품 | 급여 |
| ipratropium bromide |
an inhaled bronchodilator (trade name Atrovent)
출처: wordnet.princeton.edu/perl/webwn
|
|---|
| Ipratropium | an inhaled bronchodilator (trade name Atrovent) |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|